Last reviewed · How we verify
Placebo of Estrogen
Placebo of Estrogen is a Small molecule drug developed by Faculdade de Medicina do ABC. It is currently in Phase 3 development for Control arm in Phase 3 clinical trials of estrogen-based therapies (specific indication unknown).
A placebo formulation designed to mimic estrogen therapy for use as a control arm in clinical trials.
A placebo formulation designed to mimic estrogen therapy for use as a control arm in clinical trials. Used for Control arm in Phase 3 clinical trials of estrogen-based therapies (specific indication unknown).
At a glance
| Generic name | Placebo of Estrogen |
|---|---|
| Sponsor | Faculdade de Medicina do ABC |
| Modality | Small molecule |
| Therapeutic area | Endocrinology / Women's Health |
| Phase | Phase 3 |
Mechanism of action
This is an inert placebo preparation used in Phase 3 clinical trials to serve as a control comparator against active estrogen-based treatments. Placebos contain no pharmacologically active ingredients and are used to assess the true efficacy and safety of the investigational estrogen therapy by accounting for placebo effect and natural disease progression.
Approved indications
- Control arm in Phase 3 clinical trials of estrogen-based therapies (specific indication unknown)
Common side effects
Key clinical trials
- Menopausal Hormones and Sympathetic Activation (PHASE4)
- Romosozumab as an Adjunct to Physiologic Estrogen Replacement in Functional Hypothalamic Amenorrhea (PHASE3)
- Estradiol Supplementation and Rotator Cuff Repair (PHASE2)
- Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer (PHASE3)
- Elacestrant + Everolimus in Patients ER+/HER2-, ESR1mut, Advanced Breast Cancer Progressing to ET and CDK4/6i. (PHASE3)
- Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy for HR+/HER2- Locally Recurrent Inoperable or Metastatic Breast Cancer (MK-3475-B49/KEYNOTE-B49) (PHASE3)
- A Phase III Study of Radium-223 Dichloride in Patients With Symptomatic Hormone Refractory Prostate Cancer With Skeletal Metastases (PHASE3)
- A Study Evaluating the Efficacy and Safety of Giredestrant Combined With Palbociclib Compared With Letrozole Combined With Palbociclib in Participants With Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer (persevERA Breast Cancer) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Placebo of Estrogen CI brief — competitive landscape report
- Placebo of Estrogen updates RSS · CI watch RSS
- Faculdade de Medicina do ABC portfolio CI